4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Bicara Therapeutics Inc. (BCAX) operates in the Biotechnology industry and is headquartered in Boston, United States with about 103 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, BCAX reported $0M in revenue and ($138M) in net income.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($156M) | ($82M) | ($40M) | ($38M) |
| Net Income | ($138M) | ($68M) | ($52M) | ($38M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($60M) | ($41M) | ($41M) | ($32M) | ($42M) |
| Net Income | ($56M) | ($37M) | ($36M) | ($27M) | ($37M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Assets | $431M | $510M | $234M | $7M |
| Total Liabilities | $30M | $18M | $383M | $106M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BCAX viewer.
About TickerBase · Data methodology & sources